ClinicalTrials.gov record
Recruiting Phase 3 Interventional

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

ClinicalTrials.gov ID: NCT06650579

Public ClinicalTrials.gov record NCT06650579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: The REVELUTION-2 Trial

Study identification

NCT ID
NCT06650579
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Emory University
Other
Enrollment
72 participants

Conditions and interventions

Interventions

  • Abiraterone Acetate Drug
  • Bicalutamide Drug
  • Biospecimen Collection Procedure
  • Computed Tomography Angiography Procedure
  • Leuprolide Drug
  • Prednisone Drug
  • Radiation Therapy Radiation
  • Relugolix Drug

Drug · Procedure · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2025
Primary completion
Jun 30, 2029
Completion
Jun 30, 2029
Last update posted
Feb 23, 2026

2025 – 2029

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Emory Proton Therapy Center Atlanta Georgia 30308 Recruiting
Winship at Emory Midtown Atlanta Georgia 30308 Recruiting
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 Recruiting
Emory Saint Joseph's Hospital Atlanta Georgia 30342 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06650579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 23, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06650579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →